2023 World Conference on Lung Cancer (Posters)-P1.22. Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions.

P1.22. Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions. - PDF(Abstract)

Back to course

Pdf Summary

This abstract provides an overview of a study that aimed to determine the membranous expression of cMET in patients with advanced non-small cell lung cancer (NSCLC) and RET fusions. RET fusions are found in a small percentage of patients with aNSCLC and RET inhibitors are effective but resistance eventually occurs. Antibody-drug conjugates (ADC) are seen as promising treatments for aNSCLC and cMET is an emerging target in this setting. However, there is a lack of specific data on cMET overexpression in RET aNSCLC.<br /><br />The study collected tissue specimens from 37 patients with RET aNSCLC treated in three European centers. The expression of cMET on the cell membrane was assessed using immunohistochemistry. The study found that cMET was frequently expressed on the membrane in RET aNSCLC, suggesting that it could be explored as a target for novel treatment strategies. However, the expression of cMET did not seem to correlate with biological features or response to RET inhibitors.<br /><br />The results of the study indicate that there is potential for cMET as a therapeutic target in RET aNSCLC, but further exploration is needed. The findings also highlight the need for more research on the relationship between cMET expression and response to targeted therapies. This abstract provides important information for researchers and clinicians interested in better understanding the role of genetic biomarkers, specifically cMET expression, in the management of advanced NSCLC with RET fusions.

Asset Subtitle

Arianna Marinello

Meta Tag

Speaker Arianna Marinello

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

cMET expression

advanced non-small cell lung cancer

NSCLC

RET fusions

RET inhibitors

antibody-drug conjugates

targeted therapies

immunohistochemistry

biomarkers

genetic biomarkers